Friday 16 October 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.
1.84
0.07
−3.66%
Follow ALEC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
16.13 | 12.91 | 7.64 | 4.40 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.53) | (4.77) | (3.85) | (9.34) | |
P/B ratio |
0.00 | 22.90 | 5.24 | 5.26 | |
Price to Tangible BV |
0.00 | 22.90 | 5.24 | 5.26 | |
EV/Sales |
4.97 | 2.23 | (4.07) | 0.44 | |
EV/EBITDA |
0.00 | 0.00 | 0.56 | 0.00 | |
EV/Operating CF |
(0.44) | (0.24) | 0.47 | (0.15) | |
EV/FCF |
(0.43) | (0.24) | 0.47 | (0.15) | |
Quick Ratio |
5.05 | 5.04 | 3.68 | 3.64 | |
Current Ratio |
5.26 | 5.25 | 3.83 | 3.76 | |
Net Debt/EBITDA |
7.16 | 8.40 | 6.40 | 7.66 | |
Debt/Assets |
4.85% | 4.07% | 3.30% | 2.87% | |
Debt/Equity |
(0.99) | 0.94 | 0.32 | 0.17 | |
Asset Turnover |
0.05 | 0.06 | 0.06 | 0.16 | |
Operating CF/Net income |
1.49 | 2.17 | 1.12 | 0.94 | |
Capex/Depreciation |
(0.02) | (0.08) | 0.00 | (0.01) | |
Research and Development Expense of Revenue |
586.14% | 1,707.17% | 520.49% | 900.31% | |
Selling, General and Administrative Expense of Revenue |
248.58% | 775.14% | 213.88% | 353.31% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
78.61% | 278.01% | 77.65% | 196.38% | |
Graham Net Nets |
(0.15) | (0.06) | 0.02 | 0.08 | |
Graham Number |
1.49 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(54.73%) | (55.35%) | (89.10%) | (36.15%) | |
Free Cash Flow Yield |
(70.85%) | (72.84%) | (114.56%) | (65.06%) | |
Revenue per Share |
0.03 | 0.01 | 0.06 | 0.03 | |
Operating CF per Share |
(0.31) | (0.45) | (0.40) | (0.32) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.31) | (0.45) | (0.40) | (0.32) | |
Cash per Share |
1.55 | 1.87 | 2.49 | 2.84 | |
Shareholders Equity per Share |
(0.09) | 0.09 | 0.30 | 0.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.09) | 0.09 | 0.30 | 0.56 | |
Free Cash Flow |
(34.25) | (49.93) | (41.69) | (32.52) | |
Working Capital |
145.85 | 174.12 | 196.95 | 220.42 | |
Capital Expenditures |
(0.03) | (0.12) | 0.00 | (0.01) | |
Net Current Asset Value |
(32.74) | (14.45) | 3.86 | 22.81 | |
EV/EBIT |
0.00 | 0.00 | 0.55 | 0.00 | |
Capex to Sales |
0.01 | 0.11 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.25 | 1.87 | 1.95 | 4.89 | |
Average Assets |
279.64 | 324.11 | 380.77 | 425.65 | |
Average Common Equity |
30.60 | 52.50 | 78.72 | 88.32 |
Columns are period end dates